Dogwood Therapeutics, Inc. (DWTX) Research

Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.

Market snapshot

Symbol
DWTX
Price
$1.55
Day change
+4.03%
Market cap
$3.0M
P/E ratio
-1.84x
52-week range
1.28-9.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Bolt Biotherapeutics, Inc. (BOLT)
  • BioRestorative Therapies, Inc. (BRTX)
  • Cellectar Biosciences, Inc. (CLRB)
  • Cocrystal Pharma, Inc. (COCP)
  • Edesa Biotech, Inc. (EDSA)
  • Ernexa Therapeutics Inc. (ERNA)
  • Evogene Ltd. (EVGN)
  • Imunon, Inc. (IMNN)

Recent insider activity

  • De La Rosa Abel — A-Award (16800 shares) on 2026-06-16
  • Thomas John C — A-Award (16800 shares) on 2026-06-16
  • Whitley Richard James — A-Award (16800 shares) on 2026-06-16
  • Keefer David R — A-Award (16800 shares) on 2026-06-16
  • Grosswald Ralph — A-Award (82500 shares) on 2026-03-05

Open Dogwood Therapeutics, Inc. (DWTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.